Current Report Filing (8-k)
May 22 2017 - 4:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event
reported): May 20, 2017
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified
in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
509 Madison Avenue, Suite 306, New York,
New York 10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number,
including area code:
(212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
James M. Turner, Esq.
Sichenzia Ross Ference Kesner LLP
61 Broadway
New York, New York 10006
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company
¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On May 20, 2017, Tonix Pharmaceuticals
Holding Corp. (the “Company”) presented a poster entitled “
Phase 2 Multisite Double-Blind Placebo-Controlled
Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder: Mediators and Moderators of Treatment Response
”
(the “Poster”), at the 72
nd
Annual Scientific Convention of the Society of Biological Psychiatry, in San
Diego, California (the “SOBP Meeting”).
The foregoing description of the Poster
is qualified in its entirety by reference to the Poster, a copy of which is filed as Exhibit 99.01 to, and is incorporated
by reference in, this report.
On May 22, 2017, the Company issued a press
release announcing the Poster presentation at the SOBP Meeting. A copy of the press release that discusses this matter is filed
as Exhibit 99.02 to, and incorporated by reference in, this report.
The information in this Current Report
is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference
into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth
by specific reference in any such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
* Furnished
herewith.
SIGNATURE
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
TONIX PHARMACEUTICALS HOLDING CORP.
|
|
|
Date: May 22, 2017
|
By:
|
/s/ SETH LEDERMAN
|
|
Seth Lederman
|
|
Chief Executive Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024